相关实验视频
Updated: Sep 10, 2025

09:52
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
9.5K
乙酸通过血液迷宫屏障调节丁素的毒性
Liling Li1, Jingqian Tan1, Dan Chen1
1Department of Otolaryngology Head and Neck Surgery, The Third Affiliated Hospital of Sun Yat-Sen University, Guang Zhou, Guangdong, China, 510630.
Hearing research
|August 27, 2025
概括
乙酸 (EA) 恶化了健美素 (GM) 的耳毒性,导致严重的听力损失. N-乙半氨酸 (NAC) 可以防止这种损伤,尤其是在早期服用时,为预防药物引起的听力损失提供了一种策略.
科学领域:
- 耳毒性研究
- 药理学
- 神经科学
背景情况:
- 根他米辛 (GM) 是一种氨基糖类抗生素,导致耳毒性,限制了其临床使用.
- 与其他药物同时使用可加剧转基因诱导的耳毒性.
- 了解这些相互作用对于患者的安全至关重要.
研究的目的:
- 调查与乙烯酸 (EA) 结合的 gentamicin 的耳毒性机制.
- 评估N-乙半氨酸 (NAC) 对组合转基因和EA毒性的保护作用.
- 探索血液迷宫屏障 (BLB) 在转基因耳毒性的作用.
主要方法:
- 使用C57BL/6 J小鼠进行系统研究.
- 剂量取决于GM和EA的使用.
- 评估耳毛细胞损失,听觉神经退化和螺旋神经元损伤.
- 系统性肝脏毒性标志物的评估.
- 分析BLB完整性和围细胞介导的修复.
- 在不同时间点使用N-乙半氨酸 (NAC) 的干预.
主要成果:
- 转基因诱导的剂量依赖性耳毒性,静脉注射更为严重.
- EA在协同作用下增强了转基因的耳毒性,导致显著的毛细胞损失和神经退化.
- 它破坏了BLB的完整性,并引发了补偿性修复机制.
- NAC的干预显著减轻了转基因和EA的联合毒性,预处理显示出最好的结果.
- 延迟使用EA可减少毛细胞损伤,而NAC可改善神经和突触损伤.
结论:
- 乙酸通过破坏血液迷宫屏障的稳定性,加剧了丁胺的毒性.
- N- 乙半氨酸可以显著地保护抗 gentamicin 和乙酸联合的耳毒性.
- 服用N- 乙半氨酸的时间对其保护性有效性至关重要,为预防药物引起的听力损失提供了潜在的策略.
相关概念视频
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K
Drug Elimination by Renal Route: Tubular Secretion
2.5K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.5K
Renal Drug Excretion: Tubular Secretion
339
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
339
Drug Elimination by Renal Route: Tubular Reabsorption
3.9K
During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...
3.9K
Glomerular Filtration Rate and its Regulation
3.3K
The Glomerular Filtration Rate (GFR) is a measure of kidney function, reflecting the volume of filtrate formed per minute in the kidneys. On average, GFR is approximately 125 mL/min in males and 105 mL/min in females. Maintaining a relatively constant GFR is essential for the kidneys to effectively regulate body fluid homeostasis and maintain extracellular stability.
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
GFR regulation involves two primary intrinsic controls: the myogenic and tubuloglomerular feedback mechanisms.
The myogenic...
3.3K
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274

